A compound of Formula I wherein: A is aryl or heteroaryl, wherein said aryl or heteroaryl is optionally substituted with one or more R 1; B is H, R 1 or -L 1 -E; E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R 2; L 1 is a bond, -O-, -NH-, -N(C 1-4 alkyl)-, C 1-4 alkylene or heteroC 1-4 alkylene; wherein said heteroC 1-4 alkylene is a straight or branched C 1-4 alkylene group linked to one heteroatom selected from O, N and S, or is a straight or branched C 1-4 alkylene group wherein one or more of the carbon atoms of said alkylene group are each replaced by a heteroatom independently selected from O, N and S, wherein the nitrogen and/or sulfur heteroatom(s), if present, are optionally oxidized and wherein the nitrogen heteroatom(s), if present, may also be quaternized; L 2 is a bond and D is a cyclic group selected from: (i) a 3- to 7-membered monocyclic saturated heterocyclic ring containing 1 or 2 heteroatoms independently selected from N, O and S, and (ii) a 7- to 15-membered polycyclic ring system which comprises at least one saturated heterocyclic ring, wherein the polycyclic ring system contains from 1 to 4 heteroatoms independently selected from N, O and S, wherein the cyclic group (i) or (ii) is linked to the remainder of the compound of Formula I through a ring C atom, wherein one or more ring C atoms in the cyclic group (i) or (ii) are optionally oxidized to form CO groups, wherein one or more S atoms in the cyclic group (i) or (ii), if present, are optionally oxidized to form independently SO groups or SO 2 groups, and wherein the cyclic group (i) or (ii) is optionally substituted with one or more R 3; each R 1 is independently selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, carbocyclyl, C-amido, hydroxyl, nitro, halo, haloC 1-8 alkyl, haloC 1-8 alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C 1-8 alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; each R 2 is independently selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC 1-8 alkyl, haloC 1-8 alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C 1-8 alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; each R 3 is independently selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC 1-8 alkyl, haloC 1-8 alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C 1-8 alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; and each R w, R x, R y and R z is independently selected from hydrogen, halo and C 1-4 alkyl; or a pharmaceutically acceptable salt or solvate thereof for use as a medicament. A is aryl or heteroaryl, wherein said aryl or heteroaryl is optionally substituted with one or more R 1; B is H, R 1 or -L 1 -E; E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R 2; L 1 is a bond, -O-, -NH-, -N(C 1-4 alkyl)-, C 1-4 alkylene or heteroC 1-4 alkylene; wherein said heteroC 1-4 alkylene is a straight or branched C 1-4 alkylene group linked to one heteroatom selected from O, N and S, or is a straight or branched C 1-4 alkylene group wherein one or more of the carbon atoms of said alkylene group are each replaced by a heteroatom independently selected from O, N and S, wherein the nitrogen and/or sulfur heteroatom(s), if present, are optionally oxidized and wherein the nitrogen heteroatom(s), if present, may also be quaternized; L 2 is a bond and D is a cyclic group selected from: (i) a 3- to 7-membered monocyclic saturated heterocyclic ring containing 1 or 2 heteroatoms independently selected from N, O and S, and (ii) a 7- to 15-membered polycyclic ring system which comprises at least one saturated heterocyclic ring, wherein the polycyclic ring system contains from 1 to 4 heteroatoms independently selected from N, O and S, wherein the cyclic group (i) or (ii) is linked to the remainder of the compound of Formula I through a ring C atom, wherein one or more ring C atoms in the cyclic group (i) or (ii) are optionally oxidized to form CO groups, wherein one or more S atoms in the cyclic group (i) or (ii), if present, are optionally oxidized to form independently SO groups or SO 2 groups, and wherein the cyclic group (i) or (ii) is optionally substituted with one or more R 3; (i) a 3- to 7-membered monocyclic saturated heterocyclic ring containing 1 or 2 heteroatoms independently selected from N, O and S, and (ii) a 7- to 15-membered polycyclic ring system which comprises at least one saturated heterocyclic ring, wherein the polycyclic ring system contains from 1 to 4 heteroatoms independently selected from N, O and S, each R 1 is independently selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, carbocyclyl, C-amido, hydroxyl, nitro, halo, haloC 1-8 alkyl, haloC 1-8 alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C 1-8 alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; each R 2 is independently selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC 1-8 alkyl, haloC 1-8 alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C 1-8 alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; each R 3 is independently selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC 1-8 alkyl, haloC 1-8 alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C 1-8 alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; and each R w, R x, R y and R z is independently selected from hydrogen, halo and C 1-4 alkyl; or a pharmaceutically acceptable salt or solvate thereof for use as a medicament.